Explore the latest in cancer genetics, including advances in precision therapy from whole exome sequencing and tumor molecular profiling.
This dynamic cohort study evaluates the regional adoption of genomic testing for prostate cancer and the common trajectories of uptake shared by regions.
This cohort study uses UK Biobank data to estimate the risk for primary hepatic carcinoma and cancer-related death by HFE variant status among community-dwelling individuals of European ancestry in England, Scotland, and Wales.
This economic evaluation modeled the cost-effectiveness of 5 neoadjuvant-adjuvant treatment strategies for women with ERBB2-positive breast cancer.
This study compares pathogenic variant detection accuracy in cancer-disposition genes of prostate cancer and melanoma cohort biopsy samples using deep learning vs standard genetic analysis methods.
This economic evaluation assesses the budget impact associated with adding avapritinib for metastatic or unresectable GIST in patients with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 variant or after 3 or more previous treatments to a hypothetical US health plan formulary.
This case series study examines the prevalence of clonal hematopoiesis and its potential interference in prostate cancer cell-free DNA testing.
This cross-sectional study assesses whether the rate of positive BRCA test results changed between 2008 and 2018 among older women in the United States.
This cross-sectional study examines the association between neighborhood deprivation and estimates of epigenetic age acceleration and genome-wide methylation among women in the US and Puerto Rico.
This cost-utility analysis compares the cost-utility of these novel agents and their combinations with or without BRAF gene testing guidance for treating newly diagnosed advanced melanoma with unknown BRAF status.
This study describes expanding neurologic phenotype, cancer associations, outcomes, and immunopathologic features of Kelch-like protein-11 encephalitis.
This systematic review and meta-analysis assesses the association of the addition of daratumumab to backbone multiple myeloma regimens with progression-free survival among patients with cytogenetically defined high-risk multiple myeloma.
This open-label phase 1 study assesses the antitumor activity, tolerability, and safety of dostarlimab for patients with recurrent or advanced deficient mismatch repair endometrial cancer that has progressed after platinum-containing chemotherapy.
This decision analysis estimates the lifetime incremental incidence of hereditary breast and ovarian cancer and the quality-adjusted life-years, costs, and cost-effectiveness of hereditary breast and ovarian cancer genomic screening in an unselected population vs family history–based testing.
This genetic association study uses fine mapping of the major histocompatibility complex (MHC) region by human leukocyte antigen imputation to determine whether the HLA-B*52:01 allele is associated with cervical cancer (CC) in Japanese women.
This cohort study examines tumor mutational burden in patients with uncommon cancers not receiving immunotherapy as a biomarker associated with overall survival.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: